Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols

Haematologica

Volumn 94, Issue 1, 2009, Pages 70-77

  De Jong, Daphne ^a   Koster, Ad ^b   Hagenbeek, Anton ^c   Raemaekers, John ^d   Veldhuizen, Dennis ^a   Heisterkamp, Sabien ^a   De Boer, Jan Paul ^a   Van Glabbeke, Martine ^e  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VIECURI MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e EORTC DATA CENTER   (Belgium)

Author keywords

Follicular lymphoma; Immunohistochemistry; Microenvironment; Prognostic factors

Indexed keywords

CD68 ANTIGEN; CD69 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; PREDNISONE; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FOLLICULAR DENDRITIC CELL; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; T LYMPHOCYTE; TUMOR BIOPSY; TUMOR CELL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; BIOLOGICAL MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, FOLLICULAR; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149242769     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13574     Document Type: Article

References (28)

1. Horning SJ. Follicular lymphoma: have we made any progress? Ann Oncol 2000;11(Suppl 1):23-7.
2. Lister TA. Improved survival for patients with follicular lymphoma. J Clin Oncol 2005;23:4830-1.
3. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26.
4. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
5. Dave SS, Wright G, Tan B, Gascoyne RD, Chan WC, Fisher RI, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
6. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-8.
7. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358-63.
8. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
9. Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-9.
10. Alvaro T, Lejeune M, Salvadó MT, Lopez C, Jaén J, Bosch R, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350-7.
11. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-64.
12. Klapper W, Hoster E, Rölver L, Schrader C, Janssen D, Tiemann M, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol 2007;25:3330-6.
13. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppä S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide- doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784-9.
14. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388-97.
15. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma 2007;48:2403-11.
16. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELAGOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-6.
17. de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-12.
18. Taskinen M, Karjalainen-Lindsberg ML, Leppä S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 2008;111:4664-7.
19. Mounier N, Briere J, Gisselbrecht C Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
20. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, et al. Prognostic significance of bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-13.
21. Nyman H, Adde M, Karjalainne-Lindsberg ML, Taskinen M, Berglund M, Amini RM, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930-5.
22. Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 2006;24:1590-6.
23. Schwartz RH. Natural regulatory T cells and self-tolerance. Nat Immunol 2005;6:327-30.
24. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212-8.
25. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-25.
26. + T regulatory function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
27. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia 2008;22:49-58.
28. Kersten MJ, Jong Dd D, Raemaekers JM, Kluin PM, Hagenbeek A. Beyond the International Prognostic Index: new prognostic factors in follicular lymphoma and diffuse largecell lymphoma. A meeting report of the Second International Lunenburg Lymphoma Workshop. Hematol J 2004;5:202-8.